Limits...
Alendronate-Eluting Biphasic Calcium Phosphate (BCP) Scaffolds Stimulate Osteogenic Differentiation.

Kim SE, Yun YP, Lee DW, Kang EY, Jeong WJ, Lee B, Jeong MS, Kim HJ, Park K, Song HR - Biomed Res Int (2015)

Bottom Line: The coating of ALN on BCP scaffolds was confirmed by scanning electron microscopy (FE-SEM), energy-dispersive X-ray spectroscopy (EDS), and attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR).In vitro results revealed that MG-63 cells grown on ALN-eluting BCP scaffolds exhibited increased ALP activity and calcium deposition and upregulated gene expression of Runx2, ALP, OCN, and OPN compared with the BCP scaffold alone.Therefore, this study suggests that ALN-eluting BCP scaffolds have the potential to effectively stimulate osteogenic differentiation.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedic Surgery and Rare Diseases Institute, Korea University Medical College, Guro Hospital, No. 80, Guro-dong, Guro-gu, Seoul 152-703, Republic of Korea.

ABSTRACT
Biphasic calcium phosphate (BCP) scaffolds have been widely used in orthopedic and dental fields as osteoconductive bone substitutes. However, BCP scaffolds are not satisfactory for the stimulation of osteogenic differentiation and maturation. To enhance osteogenic differentiation, we prepared alendronate- (ALN-) eluting BCP scaffolds. The coating of ALN on BCP scaffolds was confirmed by scanning electron microscopy (FE-SEM), energy-dispersive X-ray spectroscopy (EDS), and attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR). An in vitro release study showed that release of ALN from ALN-eluting BCP scaffolds was sustained for up to 28 days. In vitro results revealed that MG-63 cells grown on ALN-eluting BCP scaffolds exhibited increased ALP activity and calcium deposition and upregulated gene expression of Runx2, ALP, OCN, and OPN compared with the BCP scaffold alone. Therefore, this study suggests that ALN-eluting BCP scaffolds have the potential to effectively stimulate osteogenic differentiation.

No MeSH data available.


In vitro release profiles of ALN from ALN (0.1 mg)/BCP and ALN (1 mg)/BCP scaffolds. These experiments were repeated three times.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4499637&req=5

fig3: In vitro release profiles of ALN from ALN (0.1 mg)/BCP and ALN (1 mg)/BCP scaffolds. These experiments were repeated three times.

Mentions: Figure 3 shows the release profiles of ALN from ALN (0.1 mg)/BCP and ALN (1 mg)/BCP scaffolds. Sustained release of ALN from ALN (0.1 mg)/BCP and ALN (1 mg)/BCP scaffolds was observed for up to 28 days. On the first day, 1.05 ± 0.03 μg and 1.46 ± 0.08 μg of ALN were released from ALN (0.1 mg)/BCP and ALN (1 mg)/BCP scaffolds, respectively. Subsequently, ALN was slowly released from the ALN/BCP scaffolds. By day 28, 2.48 ± 0.21 μg and 3.31 ± 0.31 μg of ALN were released from ALN (0.1 mg)/BCP and ALN (1 mg)/BCP scaffolds, respectively.


Alendronate-Eluting Biphasic Calcium Phosphate (BCP) Scaffolds Stimulate Osteogenic Differentiation.

Kim SE, Yun YP, Lee DW, Kang EY, Jeong WJ, Lee B, Jeong MS, Kim HJ, Park K, Song HR - Biomed Res Int (2015)

In vitro release profiles of ALN from ALN (0.1 mg)/BCP and ALN (1 mg)/BCP scaffolds. These experiments were repeated three times.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4499637&req=5

fig3: In vitro release profiles of ALN from ALN (0.1 mg)/BCP and ALN (1 mg)/BCP scaffolds. These experiments were repeated three times.
Mentions: Figure 3 shows the release profiles of ALN from ALN (0.1 mg)/BCP and ALN (1 mg)/BCP scaffolds. Sustained release of ALN from ALN (0.1 mg)/BCP and ALN (1 mg)/BCP scaffolds was observed for up to 28 days. On the first day, 1.05 ± 0.03 μg and 1.46 ± 0.08 μg of ALN were released from ALN (0.1 mg)/BCP and ALN (1 mg)/BCP scaffolds, respectively. Subsequently, ALN was slowly released from the ALN/BCP scaffolds. By day 28, 2.48 ± 0.21 μg and 3.31 ± 0.31 μg of ALN were released from ALN (0.1 mg)/BCP and ALN (1 mg)/BCP scaffolds, respectively.

Bottom Line: The coating of ALN on BCP scaffolds was confirmed by scanning electron microscopy (FE-SEM), energy-dispersive X-ray spectroscopy (EDS), and attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR).In vitro results revealed that MG-63 cells grown on ALN-eluting BCP scaffolds exhibited increased ALP activity and calcium deposition and upregulated gene expression of Runx2, ALP, OCN, and OPN compared with the BCP scaffold alone.Therefore, this study suggests that ALN-eluting BCP scaffolds have the potential to effectively stimulate osteogenic differentiation.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedic Surgery and Rare Diseases Institute, Korea University Medical College, Guro Hospital, No. 80, Guro-dong, Guro-gu, Seoul 152-703, Republic of Korea.

ABSTRACT
Biphasic calcium phosphate (BCP) scaffolds have been widely used in orthopedic and dental fields as osteoconductive bone substitutes. However, BCP scaffolds are not satisfactory for the stimulation of osteogenic differentiation and maturation. To enhance osteogenic differentiation, we prepared alendronate- (ALN-) eluting BCP scaffolds. The coating of ALN on BCP scaffolds was confirmed by scanning electron microscopy (FE-SEM), energy-dispersive X-ray spectroscopy (EDS), and attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR). An in vitro release study showed that release of ALN from ALN-eluting BCP scaffolds was sustained for up to 28 days. In vitro results revealed that MG-63 cells grown on ALN-eluting BCP scaffolds exhibited increased ALP activity and calcium deposition and upregulated gene expression of Runx2, ALP, OCN, and OPN compared with the BCP scaffold alone. Therefore, this study suggests that ALN-eluting BCP scaffolds have the potential to effectively stimulate osteogenic differentiation.

No MeSH data available.